A Study of Capecitabine (Xeloda) and Peginterferon Alfa-2a (Pegasys) in Treatment-Naive Participants With Advanced Liver Cancer
This study will evaluate the efficacy and safety of capecitabine (Xeloda) in combination with peginterferon alfa-2a (Pegasys) in participants with advanced liver cancer who have had no prior treatment. The anticipated time on study treatment is until disease progression, and the target sample size is 43 individuals.
Carcinoma, Hepatocellular
DRUG: Capecitabine|DRUG: Peginterferon alfa-2a
Objective response rate, up to post-chemotherapy follow-up ( approximately 46 months)
Time to disease progression, Up to approximately 46 months|Duration of response, Up to approximately 46 months|Overall survival, Up to approximately 46 months|Incidence of adverse events, Up to approximately 46 months
This study will evaluate the efficacy and safety of capecitabine (Xeloda) in combination with peginterferon alfa-2a (Pegasys) in participants with advanced liver cancer who have had no prior treatment. The anticipated time on study treatment is until disease progression, and the target sample size is 43 individuals.